EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY
NEWS
Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor
Oxford, UK: Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today announced it has successfully closed its latest financing round, raising a total of
Epsilogen and Lonza Announce Successful Large-Scale GMP Manufacturing of MOv18, an IgE Antibody Targeting Ovarian Cancer
LONDON, UK, and Basel, Switzerland; – Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, and Lonza, a global
Curve Therapeutics Raises £40.5 million to Turbocharge Discovery Platform and Advance Breakthrough Pipeline
Southampton, UK – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a revolutionary intracellular screening platform addressing complex and challenging disease targets,
NodThera Publishes Preclinical Data Demonstrating Reversal of Obesity and Inflammation with Clinical-stage Brain-penetrant NLRP3 Inflammasome Inhibitors
Data published in Journal of Pharmacology and Experimental Therapeutics NodThera’s brain-penetrant NLRP3 inhibitors matched weight loss driven by GLP-1 receptor agonist semaglutide (Wegovy®) or calorie
NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer
BOSTON, MA, – NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc.,
Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing
Brighton, UK: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering
EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
• Rapid improvements in key markers of disease were sustained for up to three years across all adults with PNH• Majority of patients remained transfusion
Lario Therapeutics Receives “Company Making a Difference Award” from CDLK5 Forum, Recognising its Unique Approach to Precision Medicine for Genetic Epilepsies
•“CDLK5 Forum Award for Excellence – Company Making a Difference 2023 Pre-clinical” presented by the Loulou Foundation at the CDKL5 Forum, 6th-7th November in London•First-in-class